Yair Heller Appointed CEO and Co-Founder Joseph Mossel to Lead Strategic Growth Initiatives as Ibex Accelerates Global Impact

BOSTON & TEL AVIV, Israel: Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division and U.S. clinical growth initiatives.

“Ibex has been built on a strong foundation and is entering 2026 with tremendous momentum and a clear path to scaling our platform globally,” said Yair Heller, Ibex’s Chief Executive Officer. “As we scale, we will continue delivering the most accurate and reliable tools for pathologists to help improve patient care, while also leveraging our platform to accelerate drug development pipelines and improve evidence quality worldwide.”

The company is celebrating a series of significant commercial milestones, including strategically important clinical deployments with two of the largest laboratory networks in Europe, as well as PathGroup and HNL Lab Medicine in the U.S., as well as significant expansions from existing customers such as Fimlab in Finland. These partnerships underscore the global shift toward AI-powered pathology as the gold standard for cancer detection.

Reflecting this momentum, Ibex doubled the total number of cases running through its platform for the second straight year, grew its customer base by more than 70%, and increased the number of new applications running live in 2025 to more than three times 2024 levels.

“Ibex enables us to deliver a new level of diagnostic precision, moving confidently to accurately diagnose more patients,” said Derek C. Welch, M.D., President and Chief Medical Officer at PathGroup. “Ibex strengthens our ability to support clinicians with timely, high-confidence results, and positions us to scale that impact as demand continues to grow.”

Simultaneously, under Mossel’s leadership, Ibex is accelerating its expansion into the life sciences by enhancing its platform to support drug development from biomarker assessment and clinical trial optimization through regulatory clearance and clinical deployment.

A central pillar of this strategy is the precise quantification of IHC-based biomarkers, a capability central for the development of Antibody-Drug Conjugates. By delivering objective, computational scoring of target expression, Ibex enables its biopharma partners to optimize patient selection, strengthen clinical evidence generation, and bridge the gap between clinical validation and real-world implementation.

“Leading Ibex as CEO has been one of the great privileges of my career, and I’m incredibly proud of what we’ve built so far,” said Joseph Mossel, President and General Manager, U.S. “I have the utmost confidence in Yair’s leadership to drive our next phase of growth. With the company in such capable hands, I am thrilled to now focus my energy on our growing biopharma business. We have a unique opportunity to help bring life-saving treatments to market faster, and I look forward to working closely with our partners to achieve this goal.”

About Ibex Medical Analytics

Ibex is a global leader in clinical-grade AI for pathology, with hundreds of clinically deployed solutions and partnerships spanning life-science companies, reference laboratories, and digital pathology vendors. Ibex’s platform supports biomarker discovery, clinical trial efficiency, and CDx-ready evidence generation, backed by an ISO 13485-compliant QMS.

The Ibex platform includes solutions that are CE-IVD certified and registered with the UK MHRA, TGA in Australia and ANVISA in Brazil. It includes a solution that is FDA cleared and others that are Research Use Only (RUO) in the United States.

Fonte: Business Wire